AI Article Synopsis
- The study focused on assessing the effectiveness and safety of lotilaner ophthalmic solution (0.25% eyedrops) for treating blepharitis compared to a placebo (vehicle).
- A total of 54 participants were involved in a double-blind trial, receiving either the lotilaner solution or the control solution twice a day for 42 days, measuring outcomes like collarette cure and mite eradication.
- Results showed a significantly higher success rate in achieving collarette cure (80% vs. 15.8%), mite eradication (73.3% vs. 21.1%), and composite cure (73.3% vs. 10.5%) in the lotilaner group, indicating it is a safe
Article Abstract
Purpose: To evaluate the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops compared to vehicle for the treatment of blepharitis.
Methods: In this randomized, controlled, double-masked clinical trial, 54 participants were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmic solution, 0.25% (study group) or the vehicle (control group) bilaterally, twice daily for 42 days. Outcome measures were collarette cure (collarette grade 0, upper eyelid), mite eradication (mite density of 0 mites/lash), and composite cure (grade 0 for collarettes and erythema).
Results: The proportion of participants achieving collarette cure (80.0% vs 15.8%; p < .001), mite eradication (73.3% vs 21.1%, p = .003) and composite cure (73.3% vs 10.5%, p < .001) at Day 42 was statistically significantly higher in the study group than the control group.
Conclusion: Twice-daily 42-day treatment with novel lotilaner ophthalmic solution, 0.25% is safe and effective for the treatment of blepharitis compared to the vehicle control. (Registry number: ACTRN12620000320954, dated 09/03/2020).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2022.2093755 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multidisciplinary perspectives in blepharitis: A new view of treatment from clinical, payer, and patient perspectives.
J Manag Care Spec Pharm
October 2024
Advantific, LLC, Princeton, NJ.
Article Synopsis
- Infestation is responsible for over two-thirds of blepharitis cases in the U.S., indicated by symptoms like crusty, red, or itchy eyelids and identifiable collarettes on eyelashes.
- Lotilaner ophthalmic solution 0.25% is the first FDA-approved treatment for blepharitis that effectively eliminates mites in 50-67% of patients after short-term use, with benefits lasting up to one year.
- By addressing the infestation that causes blepharitis, eye care professionals can improve overall patient outcomes, reduce the need for ongoing care, and optimize healthcare resource usage within the community.
Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.
J Ocul Pharmacol Ther
November 2024
Tarsus Pharmaceuticals, Irvine, California, USA.
Article Synopsis
- - The study evaluated how lotilaner ophthalmic solution (0.25%) is absorbed and distributed in the eyes and body of Dutch-belted rabbits after single and repeated doses.
- - Rabbits received either one dose or doses twice daily for a week, and drug levels were tested in ocular tissues and blood for pharmacokinetics metrics.
- - Results showed high drug concentrations in eyelid margins, with a long half-life of about 6.3 days in the repeated dose group, and no adverse effects noted from the treatment.
Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Blepharitis.
Healthcare (Basel)
July 2024
Virginia Eye Consultants, Norfolk, VA 23502, USA.
Article Synopsis
- Blepharitis is a chronic eyelid condition primarily caused by mites infesting the eyelid margins, and it is now treatable with Lotilaner ophthalmic solution (0.25%), which is the first approved therapy for this condition.
- Clinical studies involving 980 patients demonstrated that Lotilaner effectively reduced the number of collarettes (waxy debris at the eyelashes) by 81-93% and achieved a mite eradication rate of 52-78%.
- The treatment showed a good safety profile, with no serious adverse events reported, and 92% of patients described the eyedrops as comfortable, indicating it may become the standard treatment for blepharitis.
Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials.
Cont Lens Anterior Eye
June 2024
Adventhealth Sebring, FL, USA.
Article Synopsis
- Demodex blepharitis is a condition caused by Demodex mites that affects the eyelids and may require specialized treatments, as current options might not work effectively.
- A systematic review analyzed five studies to assess the efficacy of 0.25% lotilaner ophthalmic solution in treating this condition, focusing on its ability to reduce mite populations and inflammation.
- Results indicated that lotilaner significantly improves eyelid conditions, eradicating mites and reducing symptoms, outperforming placebo in curing related issues like collarette and erythema.
Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies.
Am J Ophthalmol
August 2024
Department of Nursing, Hamad Medical Corporation (A.J.N.), Doha, Qatar; Department of Public Health, College of Health Sciences, QU Health, Qatar University (A.J.N.), Doha, Qatar. Electronic address:
Article Synopsis
- Several treatments for Demodex blepharitis exist, but they often have undesirable side effects; lotilaner is proposed as a safer alternative.
- A systematic review and meta-analysis, analyzing six relevant studies, determined lotilaner's effectiveness in eradicating Demodex mites.
- Results indicate that lotilaner is not only effective but also well-tolerated, suggesting it could be a promising treatment option for Demodex blepharitis, and consideration of cost-effectiveness is encouraged.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!